title: Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy.
abstract: BACKGROUND
  Triple-negative breast cancer (TNBC) is a special subtype of breast cancer that is characterized by poor prognosis, strong tumor invasion and a high pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC). The pCR rate is a prognostic factor for TNBC. We aimed to evaluate the relationship between pCR and TNBC after NAC and originally tried to identify factors related to achieving pCR for TNBC using a meta-analysis.
  
  
  METHODS
  We systematically searched the literature for pCR and breast cancer after NAC and carefully identified eligibility criteria. The association between pCR and breast cancer subtypes was estimated using Review Manager, while pCR rates for TNBC and non-TNBC were determined using Meta-Analyst.
  
  
  RESULTS
  This analysis included a total of 9,460 cases from 27 studies. The summary odds ratio estimating the relationship between pCR and breast cancer subtypes (TNBC vs non-TNBC) was 3.02 (95% confidence interval (CI), 2.66 to 3.42). The TNBC pCR rate was 28.9% (95% CI, 27.0 to 30.8%) and the non-TNBC was 12.5% (95% CI, 11.7 to 13.4%). From subgroup analyses, we identified the factors associated with the highest pCR rates for TNBC.
  
  
  CONCLUSIONS
  TNBC has a higher pCR rate than non-TNBC. In the NAC setting, these factors of platinum-containing, more than six cycles, four kinds of drugs, 16 weeks' treatment duration and sequential chemotherapy may contribute to increasing the pCR rate.
authors.forename: Kunpeng
authors.initials: K
authors.lastname: Wu
authors.forename: Qiaozhu
authors.initials: Q
authors.lastname: Yang
authors.forename: Yi
authors.initials: Y
authors.lastname: Liu
authors.affiliation: Cancer Center, Affiliated Hospital of Guangdong Medical College, 57 Renmin Road, Zhanjiang, PR China. wab801016@163.com.
authors.forename: Aibing
authors.initials: A
authors.lastname: Wu
authors.forename: Zhixiong
authors.initials: Z
authors.lastname: Yang
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000145:classification / Q000188:drug therapy* / Q000473:pathology; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D020360:Neoadjuvant Therapy; D009362:Neoplasm Metastasis; D009944:Organoplatinum Compounds / Q000627:therapeutic use*; D011379:Prognosis; D012074:Remission Induction; D064726:Triple Negative Breast Neoplasms / Q000145:classification / Q000188:drug therapy* / Q000473:pathology
chemical_list: D009944:Organoplatinum Compounds
references.citation: Eur J Cancer. 2011 Sep;47(14):2084-90
references.pmid: 21737257
references.citation: Breast Cancer Res. 2006;8(6):R66
references.pmid: 17129383
references.citation: BMC Cancer. 2007 Nov 01;7:203
references.pmid: 17976237
references.citation: Breast Cancer Res Treat. 2010 Jul;122(2):429-37
references.pmid: 20480225
references.citation: Clin Cancer Res. 2007 Apr 15;13(8):2329-34
references.pmid: 17438091
references.citation: Cancer. 2007 May 1;109(9):1721-8
references.pmid: 17387718
references.citation: Nature. 2000 Aug 17;406(6797):747-52
references.pmid: 10963602
references.citation: N Engl J Med. 2010 Nov 11;363(20):1938-48
references.pmid: 21067385
references.citation: Clin Transl Oncol. 2008 Oct;10(10):646-53
references.pmid: 18940745
references.citation: J Clin Pathol. 2011 Feb;64(2):130-5
references.pmid: 21148141
references.citation: Breast Cancer Res. 2009;11(5):R69
references.pmid: 19758440
references.citation: Breast Cancer Res Treat. 2013 Feb;138(1):21-35
references.pmid: 23358903
references.citation: Breast. 2010 Jun;19(3):246-8
references.pmid: 20227277
references.citation: Breast Cancer. 2011 Jul;18(3):152-60
references.pmid: 21086082
references.citation: Ann Surg Oncol. 2010 Sep;17(9):2411-8
references.pmid: 20373039
references.citation: Eur J Cancer. 2012 Dec;48(18):3342-54
references.pmid: 22766518
references.citation: Breast Cancer Res Treat. 2012 Apr;132(3):793-805
references.pmid: 21562709
references.citation: J Clin Oncol. 2012 May 20;30(15):1796-804
references.pmid: 22508812
references.citation: Am J Clin Oncol. 2012 Jun;35(3):242-6
references.pmid: 21358298
references.citation: Ann Oncol. 2010 May;21(5):961-7
references.pmid: 20211870
references.citation: Ann Oncol. 2008 Nov;19(11):1847-52
references.pmid: 18567607
references.citation: Ann Oncol. 2013 May;24(5):1219-25
references.pmid: 23223332
references.citation: Drugs R D. 2011;11(2):147-57
references.pmid: 21679005
references.citation: Arch Pathol Lab Med. 2010 Jul;134(7):e48-72
references.pmid: 20586616
references.citation: J Clin Oncol. 2011 Feb 20;29(6):660-6
references.pmid: 21220595
references.citation: J Clin Oncol. 2012 May 20;30(15):1879-87
references.pmid: 22454417
references.citation: J Clin Oncol. 2011 Nov 20;29(33):4373-80
references.pmid: 22010008
references.citation: Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34
references.pmid: 17671126
references.citation: Invest New Drugs. 2010 Dec;28(6):859-65
references.pmid: 19705063
references.citation: Breast Cancer Res Treat. 2011 Jul;128(1):127-36
references.pmid: 21465170
references.citation: Cancer. 2007 Oct 15;110(8):1687-96
references.pmid: 17722109
references.citation: Cochrane Database Syst Rev. 2007 Apr 18;(2):CD005002
references.pmid: 17443564
references.citation: Ann Oncol. 2012 Sep;23(9):2223-2234
references.pmid: 22517820
references.citation: Cancer. 2010 Sep 15;116(18):4227-37
references.pmid: 20549829
references.citation: Breast Cancer Res Treat. 2009 May;115(2):423-8
references.pmid: 18543098
references.citation: Br J Cancer. 2008 Apr 22;98(8):1327-35
references.pmid: 18382427
references.citation: Clin Cancer Res. 2005 Aug 15;11(16):5678-85
references.pmid: 16115903
references.citation: Ann Oncol. 2012 Aug;23 Suppl 6:vi19-22
references.pmid: 23012297
references.citation: Cancer. 2012 Jan 15;118(2):326-32
references.pmid: 21590688
references.citation: Oncol Rep. 2009 Feb;21(2):413-7
references.pmid: 19148516
references.citation: Cancer. 2010 Mar 15;116(6):1431-9
references.pmid: 20131351
references.citation: Jpn J Clin Oncol. 2011 Jul;41(7):867-75
references.pmid: 21719750
references.citation: J Clin Oncol. 2010 Mar 1;28(7):1145-53
references.pmid: 20100965
references.citation: Ann Oncol. 2008 Jul;19(7):1261-1265
references.pmid: 18325917
references.citation: Int J Cancer. 2009 Mar 15;124(6):1457-62
references.pmid: 19065658
references.citation: Oncol Rep. 2010 May;23(5):1213-20
references.pmid: 20372832
references.citation: BMC Cancer. 2007 Jul 24;7:134
references.pmid: 17650314
references.citation: Clin Cancer Res. 2008 Mar 1;14(5):1368-76
references.pmid: 18316557
references.citation: J Pathol. 2010 Jan;220(2):263-80
references.pmid: 19927298
references.citation: Cancer. 2007 Jan 1;109(1):25-32
references.pmid: 17146782
references.citation: Ann Oncol. 2012 Aug;23 Suppl 6:vi7-12
references.pmid: 23012306
references.citation: Cancer. 2010 Sep 1;116(17):4168-77
references.pmid: 20564153
references.citation: Breast Cancer Res Treat. 2011 Aug;129(1):185-90
references.pmid: 21394499
references.citation: Breast Cancer Res Treat. 2010 Nov;124(1):133-40
references.pmid: 20697801
references.citation: J Clin Oncol. 2009 Oct 1;27(28):4693-700
references.pmid: 19720916
references.citation: J Natl Cancer Inst. 2004 Nov 17;96(22):1659-68
references.pmid: 15547178
references.citation: Oncology. 2010;79(5-6):324-30
references.pmid: 21430399
references.citation: Breast Cancer Res Treat. 2011 Apr;126(2):463-70
references.pmid: 21234672
references.citation: Ann Oncol. 2011 Apr;22(4):848-856
references.pmid: 20924076
references.citation: J Cancer Res Clin Oncol. 2011 Oct;137(10):1505-10
references.pmid: 21830158
references.citation: J Clin Oncol. 2008 Mar 10;26(8):1275-81
references.pmid: 18250347